Leerink believes the post-earnings selloff in Intuitive Surgical (ISRG) shares creates an attractive buying opportunity. The firm believes the Street is getting the story wrong and that the pullback does not reflect the strength of the company’s underlying fundamentals. The U.S. DV5 launch suggests potentially underappreciated outside the U.S. acceleration in the second half of 2026, the analyst tells investors in a research note. Leerink reiterates an Outperform rating on Intuitive Surgical with a $593 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical’s New Study: A Closer Look at the Ion Endoluminal System
- Intuitive Surgical’s Strong Performance and Growth Potential Reinforce Buy Rating
- Intuitive Surgical’s Earnings Call: Growth Amid Challenges
- Intuitive Surgical price target raised to $600 from $590 at Baird
- Intuitive Surgical price target lowered to $535 from $550 at Evercore ISI